Epidermodysplasia Verruciformis (EV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Epidermodysplasia verruciformis (EV), commonly referred to as tree man syndrome, is an uncommon lifelong cutaneous disorder caused by autosomal recessive immune system anomalies, leading to heightened vulnerability to cutaneous human papillomavirus (HPV) infections, typically emerging in childhood. The onset of symptoms typically occurs during infancy (7.5% of cases), youth (61.5% of cases), or puberty (22% of cases), marked by the gradual emergence of flat wart-like papules, irregular reddish-brown plaques, seborrheic keratosis-like lesions, and pityriasis Versicolor-like macules on various body areas including the trunk, neck, face, dorsal hands, and feet. The condition arises from loss-of-function mutations affecting either EVER1/TMC6 or EVER2/TMC8 genes located on chromosome 17q25.3, which encode membrane proteins forming a complex with the zinc transporter ZnT-1 in the ER membrane of keratinocytes. Two distinct clinical presentations of EV have been observed: flat-topped papules and plaques with scaly surfaces and irregular borders, exhibiting colors ranging from white to pink, reddish-brown, dark brown, or violet; and verrucous or seborrhoeic keratosis-like lesions, characterized by raised brown warty appearances. The management of EV involves various treatment modalities, including oral and topical retinoids, fluorouracil, and imiquimod. Chemical treatment, cryotherapy, electrosurgery, laser ablation, and ALA-PDT (photodynamic therapy with aminolevulinic acid) are employed.
• The prevalence of EVs in the USA is estimated to range from 0.5 to 0.75 cases per million population.

Thelansis’s “Epidermodysplasia Verruciformis (EV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epidermodysplasia Verruciformis (EV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Epidermodysplasia Verruciformis (EV) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Epidermodysplasia Verruciformis (EV) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Epidermodysplasia Verruciformis (EV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033